Bayer Pharmaceuticals is conducting a study to test the efficacy of its anticoagulant Xarelto in patients who are recovering from a stroke. The blood-thinner is currently used with patients who have suffered atrial fibrillation, deep vein thrombosis or are undergoing knee or hip surgery—though many patients have reported serious Xarelto side effects.
Xarelto was approved for certain uses by the U.S. Food and Drug Administration (FDA) in 2011. Although Bayer has lobbied for expanded use of the drug, the FDA has cited a requirement for more Xarelto research to determine potential risks associated with the drug, including reported cases of pulmonary embolism and deep vein thrombosis.
Xarelto has been associated with more than 1,800 adverse events since its approval in 2011, including 183 deaths. The drug does not contain an antidote, which means that many of the Xarelto complications, such as excessive bleeding and internal hemorrhaging, are difficult to reverse.